Stock ZYME ZYMEWORKS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Zymeworks Inc.

Equities

ZYME

US98985Y1082

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
8.51 USD +1.19% Intraday chart for Zymeworks Inc. +1.19% -18.09%
06-17 Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy MT
06-17 Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers DJ

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy
MT
Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers
DJ
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
GL
Transcript : Zymeworks Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:58 PM
Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
CI
Sector Update: Health Care Stocks Decline Premarket Monday
MT
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy
MT
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
GL
Zymeworks Announces Participation in Upcoming Investor Conferences
GL
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)
BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
PR
Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
GL
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Unlocking the potential of antibody drug conjugates
AQ
Zymeworks Announces Participation in Upcoming Investor Conferences
GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZYME Stock
  4. News Zymeworks Inc.